Suven Life Science grabs a patent by Australia for a drug used in the treatment of neuro-degenerative diseases.

Suven Life said it has been granted "one product patent from India corresponding to the New Chemical Entities (NCEs) for the treatment of d...

In a BSE filing today, it said it has been granted "one product patent from Europe and two patents from Eurasia corresponding to New Chemic...

The new chemical entities (NCEs) are being developed for the treatment of cognitive impairment associated with neuro-degenerative disorders.

With these new patents, Suven has a total of 24 granted patents from Australia, 17 from Eurasia and 9 from Israel and 24 from the US.

Suven Life Sciences has been granted a patent each by China, Eurasia and Hong Kong for a drug used in the treatment of neuro-degenerative d...

With these new patents, Suven has a total of 23 granted patents from Australia and 22 from Canada.

Suven Life Sciences has been granted a patent each by Canada, South Korea and ARIPO for a drug used in the treatment of neuro-degenerative ...

Suven Life Sciences has been granted a patent each by Europe and Macau for drug used in the treatment of disorders associated with neurodeg...

Drug firm Suven Life Sciences has been granted a patent each by Eurasia, Europe, Israel and Macau for a drug used in the treatment of neuro...

With these new patents, Suven has a total of 22 granted patents from Australia, 19 from China, 17 from Europe, 17 from South Korea and 23 f...

In a BSE filing, the company said that it 'secured patents from China and South Africa to the new chemical entities (NCE) for central nervo...

With these new patents for treatment of neurodegenerative diseases, Suven has a total of 18 granted patents from Mexico and 20 from Singapo...

Co said it has been granted one patent each by Europe and Hong Kong for a drug used in the treatment of neurodegenerative diseases.

The firm has been granted patents each by Canada, Japan and Korea for molecules, aimed to be developed as drugs, for the treatment of neuro...

These patents are valid until 2029. With the new patents, Suven has a total of 13 granted patents 12 from Eurasia, 12 from Japan and 17 fro...

Drug firm Suven Life Sciences today said it has received three product patents for CNS molecules, two from Eurasia and one from Canada.